Note 14 - Subsequent Event |
6 Months Ended |
|---|---|
Jun. 30, 2019 | |
| Notes to Financial Statements | |
| Subsequent Events [Text Block] |
1 4 . S
ubsequent Event
Subsequent to the end of the quarter ended June 30, 2019, our wholly owned subsidiary, DiaMedica Australia Pty Ltd, received the research and development incentive payment of approximately $650,000 for 2018 qualifying research activities.As described in Note 12, titled “License and Collaboration Agreement with Related Party,” on August 12, 2019, we terminated the License Agreement with Ahon Pharma for non-payment of the $4.5 million milestone due upon the earlier of regulatory clearance to initiate a clinical trial in China or July 1, 2019, thereby regaining worldwide rights for DM199 for acute ischemic stroke. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|